Under construction – not a live service
Sign in
Taking people in NorwayNo phase

Studying pain mechanisms in people with inflammatory joint diseases

Studies why chronic pain happens in people with inflammatory arthritis over time.

Plain-language title generated from the registry record
Registry title: Pain in Inflammatory Joint Diseases

Key facts

Where
Oslo, NorwaySee the site

Where in Norway

  • Diakonhjemmet HospitalOslo, NorwayTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Diakonhjemmet Hospital
Trial code
NCT06718569
Record updated
13 April 2026
Original description
Our primary objective is to better understand the etiology and consequences of chronic paint by using an explorative approach to identify phenotypes and endotypes of patients with inflammatory joint diseases, with a special focus on central sensitization and cognitive functioning as a key element in chronic pain. We will also examine the risk factors and clinical impact of these factors on pain, disease activity and treatment effects in a longitudinal study of patients with inflammatory joint disesases.Read full original descriptionShow less

Advancing the Understanding of Pain Mechanisms in Inflammatory Arthritis Towards Precision Pain Management

Our primary objective is to better understand the etiology and consequences of chronic paint by using an explorative approach to identify phenotypes and endotypes of patients with inflammatory joint diseases, with a special focus on central sensitization and cognitive functioning as a key element in chronic pain. We will also examine the risk factors and clinical impact of these factors on pain, disease activity and treatment effects in a longitudinal study of patients with inflammatory joint disesases.

Inclusion: All patients who initiate or switch biological or targeted synthetic DMARDs.

Exclusion: None.

ClinicalTrials.gov NCT06718569